A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients

Trastuzumab is a standard treatment for HER2-positive (HER2(+)) breast cancer, but some patients are refractory to the therapy. MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2(+) metastatic breast cancer (MBC)...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Nat Commun
Egile Nagusiak: Li, Huiping, Liu, Jiang, Chen, Jianing, Wang, Huiyun, Yang, Linbin, Chen, Fei, Fan, Siting, Wang, Jing, Shao, Bin, Yin, Dong, Zeng, Musheng, Li, Mengfeng, Li, Jun, Su, Fengxi, Liu, Qiang, Yao, Herui, Su, Shicheng, Song, Erwei
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Nature Publishing Group UK 2018
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5915573/
https://ncbi.nlm.nih.gov/pubmed/29691399
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41467-018-03537-w
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak